These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16271446)

  • 21. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
    Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
    Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
    Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
    Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.
    Wada M
    Cancer Lett; 2006 Mar; 234(1):40-50. PubMed ID: 16377077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of pharmacogenetics in irinotecan therapy.
    de Jong FA; de Jonge MJ; Verweij J; Mathijssen RH
    Cancer Lett; 2006 Mar; 234(1):90-106. PubMed ID: 16343744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
    de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
    Nagar S; Blanchard RL
    Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
    Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
    Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
    Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and function of multidrug resistance transporters at the blood-brain barriers.
    Scherrmann JM
    Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):233-46. PubMed ID: 16922639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
    Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
    Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of irinotecan.
    Toffoli G; Cecchin E; Corona G; Boiocchi M
    Curr Med Chem Anticancer Agents; 2003 May; 3(3):225-37. PubMed ID: 12769780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
    van der Bol JM; Mathijssen RH; Creemers GJ; Planting AS; Loos WJ; Wiemer EA; Friberg LE; Verweij J; Sparreboom A; de Jong FA
    Clin Cancer Res; 2010 Jan; 16(2):736-42. PubMed ID: 20068078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
    Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
    Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
    Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
    Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.
    Colombo S; Soranzo N; Rotger M; Sprenger R; Bleiber G; Furrer H; Buclin T; Goldstein D; Décosterd L; Telenti A;
    Pharmacogenet Genomics; 2005 Sep; 15(9):599-608. PubMed ID: 16041239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic pathway analysis of irinotecan.
    Rosner GL; Panetta JC; Innocenti F; Ratain MJ
    Clin Pharmacol Ther; 2008 Sep; 84(3):393-402. PubMed ID: 18418374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.
    Tagen M; Zhuang Y; Zhang F; Harstead KE; Shen J; Schaiquevich P; Fraga CH; Panetta JC; Waters CM; Stewart CF
    Drug Metab Lett; 2010 Dec; 4(4):195-201. PubMed ID: 20583968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.